Latest News & Features
Refine Search
Europe
London’s MedCity is working to boost collaboration between businesses in the area and invigorate the UK’s so-called ‘golden triangle’ life sciences cluster, with its three major centres in London, Oxford and Cambridge. LSIPR heard from Eliot Forster, who chairs MedCity, about the initiative. 30 May 2014
Americas
With the Federal Circuit relying on the precedent set by the Prometheus and Myriad decisions, Dolly the sheep has been summarily declared ineligible for patent protection. Nabeela Rasheed sums up the implications. 30 May 2014
Europe
London-based imaging company Imanova develops ‘imaging biomarkers’ to support the business of drug discovery, and takes a novel approach to protecting its innovations. LSIPR spoke to chief executive Kevin Cox about the company’s strategy. 30 May 2014
Americas
The new examination guidelines do not carry the weight of law, and it is not likely that their more extreme aspects will withstand judicial scrutiny, but practitioners need to keep tabs on court decisions, says Courtenay C. Brinckerhoff. 30 May 2014
Americas
With careful patent drafting and prosecution, it is possible to capture significant IP value in the clinically—and commercially—important area of biomarkers, says Stephanie Pilkington of Potter Clarkson. 30 April 2014
Asia
International damage may result from India’s steps to formalise its isolationist patents regime, says Jason Rutt. 30 April 2014
Asia
Arguments over the term of the patents granted are at the heart of the Copaxone conflict, says Archana Shanker. 30 April 2014
Europe
Horizon Discovery’s cell line-creating technology has the potential to advance personalised medicine. But how does the gene editing company stay
competitive in a crowded field? LSIPR found out. 30 April 2014
article
Many researchers are unaware of the legalities when it comes to sharing and using copyrighted material, but licensing agreements can help, says Kate Alzapiedi of copyright licensing firm RightsDirect. 31 March 2014
Asia
Strand Life Sciences’ ‘virtual’ liver could cut the failure rate of drug development by giving researchers a clearer idea which of the potential drugs are unlikely to work. How does the Bangalore-based company protect and license its technology? 31 March 2014